Please login to the form below

Not currently logged in
Email:
Password:

Akynzeo

This page shows the latest Akynzeo news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was

Latest news

  • Eisai wins US approval for chemotherapy side effects drug Eisai wins US approval for chemotherapy side effects drug

    Eisai wins US approval for chemotherapy side effects drug. FDA backs Akynzeo to treat nausea and vomiting. ... Combined, these studies involved 1, 720 people receiving chemotherapy, with groups split between those taking Akynzeo and those on Aloxi.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics